Jasper Edgar Neggers

Jasper Edgar Neggers

Auto-generated profile, based on publicly available information

Jasper Edgar Neggers

KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, 3000 Leuven, Belgium

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2016 in Nature
Verified
Journal Article
Closed access
PDF file
JKJimi Kim
Jimi Kim
EMElizabeth McMillan
Elizabeth McMillan
HKHyun Seok Kim
Hyun Seok Kim
NVNiranjan Venkateswaran
Niranjan Venkateswaran
GMGurbani Makkar
Gurbani Makkar
MWMichael A. White
Michael A. White

1 January 2015 in Chemistry & Biology
Verified
Journal Article
Closed access
JNJasper E. Neggers
Jasper E. Neggers
TVThomas Vercruysse
Thomas Vercruysse
MJMaarten Jacquemyn
Maarten Jacquemyn
EVEls Vanstreels
Els Vanstreels
EBErkan Baloglu
Erkan Baloglu
DDDirk Daelemans
Dirk Daelemans

5 February 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
JNJasper Edgar Neggers
Jasper Edgar Neggers
BKBert Kwanten
Bert Kwanten
TDTim Dierckx
Tim Dierckx
HNHiroki Noguchi
Hiroki Noguchi
AVArnout Voet
Arnout Voet
DDDirk Daelemans
Dirk Daelemans
Unraveling the mechanism of action and molecular target of small molecules remains a major challenge in drug discovery. While many cancer drugs target genetic vulnerabilities, loss-of-function screens fail to identify essential genes in drug mechanism of action. Here, we report CRISPRres, a CRISPR-Cas-based genetic screening approach to rapidly derive and identify drug resistance mutations in essential genes. It exploits the local genetic variation created by CRISPR-Cas-induced non-homologous end-joining (NHEJ) repair to generate a wide variety of functional in-frame mutations. Using large sgRNA tiling libraries and known drug–target pairs, we validate it as a target identification approach. We apply CRISPRres to the anticancer agent KPT-9274 and identify nicotinamide phosphoribosyltransferase (NAMPT) as its main target. These results present a powerful and simple genetic approach to create many protein variants that, in combination with positive selection, can be applied to reveal the cellular target of small-molecule inhibitors.

14 May 2017 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
TVThomas Vercruysse
Thomas Vercruysse
JBJolien De Bie
Jolien De Bie
JNJasper E. Neggers
Jasper E. Neggers
MJMaarten Jacquemyn
Maarten Jacquemyn
EVEls Vanstreels
Els Vanstreels
DDDirk Daelemans
Dirk Daelemans
Purpose: Human exportin-1 (XPO1) is the key nuclear-cytoplasmic transport protein that exports different cargo proteins out of the nucleus. Inducing nuclear accumulation of these proteins by inhibiting XPO1 causes cancer cell death. First clinical validation of pharmacological inhibition of XPO1 was obtained with the Selective Inhibitor of Nuclear Export (SINE) compound selinexor (KPT-330) demonstrating activity in phase-II/IIb clinical trials when dosed 1 to 3 times weekly. The second-generation SINE compound KPT-8602 shows improved tolerability and can be dosed daily. Here, we investigate and validate the drug–target interaction of KPT-8602 and explore its activity against acute lymphoblastic leukemia (ALL). Experimental Design: We examined the effect of KPT-8602 on XPO1 function and XPO1-cargo as well as on a panel of leukemia cell lines. Mutant XPO1 leukemia cells were designed to validate KPT-8602′s drug-target interaction. In vivo, anti-ALL activity was measured in a mouse ALL model and patient-derived ALL xenograft models. Results: KPT-8602 induced caspase-dependent apoptosis in a panel of leukemic cell lines in vitro. Using CRISPR/Cas9 genome editing, we demonstrated the specificity of KPT-8602 for cysteine 528 in the cargo-binding groove of XPO1 and validated the drug target interaction. In vivo, KPT-8602 showed potent anti-leukemia activity in a mouse ALL model as well as in patient-derived T- and B-ALL xenograft models without affecting normal hematopoiesis. Conclusions: KPT-8602 is highly specific for XPO1 inhibition and demonstrates potent anti-leukemic activity supporting clinical application of the second-generation SINE compound for the treatment of ALL. Clin Cancer Res; 23(10); 2528–41. ©2016 AACR.

1 December 2020 in Cell Reports
Verified
Journal Article
Open access
JNJasper E. Neggers
Jasper E. Neggers
BPBrenton R. Paolella
Brenton R. Paolella
AAAdhana Asfaw
Adhana Asfaw
MRMichael V. Rothberg
Michael V. Rothberg
TSThomas A. Skipper
Thomas A. Skipper
AAAndrew J. Aguirre
Andrew J. Aguirre
Few therapies target the loss of tumor suppressor genes in cancer. We examine CRISPR-SpCas9 and RNA-interference loss-of-function screens to identify new therapeutic targets associated with genomic loss of tumor suppressor genes. The endosomal sorting complexes required for transport (ESCRT) ATPases VPS4A and VPS4B score as strong synthetic lethal dependencies. VPS4A is essential in cancers harboring loss of VPS4B adjacent to SMAD4 on chromosome 18q and VPS4B is required in tumors with co-deletion of VPS4A and CDH1 (E-cadherin) on chromosome 16q. We demonstrate that more than 30% of cancers selectively require VPS4A or VPS4B. VPS4A suppression in VPS4B-deficient cells selectively leads to ESCRT-III filament accumulation, cytokinesis defects, nuclear deformation, G2/M arrest, apoptosis, and potent tumor regression. CRISPR-SpCas9 screening and integrative genomic analysis reveal other ESCRT members, regulators of abscission, and interferon signaling as modifiers of VPS4A dependency. We describe a compendium of synthetic lethal vulnerabilities and nominate VPS4A and VPS4B as high-priority therapeutic targets for cancers with 18q or 16q loss.

13 March 2020 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
Asfar AzmiAsfar Azmi
Asfar Azmi
HKHusain Yar Khan
Husain Yar Khan
IMIrfana Muqbil
Irfana Muqbil
AAAmro Aboukameel
Amro Aboukameel
JNJasper E. Neggers
Jasper E. Neggers
PPPhilip A. Philip
Philip A. Philip
Purpose: Pancreatic ductal adenocarcinoma (PDAC) remains a deadly disease urgently requiring new treatments. Overexpression of the protein transporter exportin-1 (XPO1) leads to mislocalization of tumor-suppressor proteins (TSP) and their inactivation. Earlier, we showed that blocking XPO1 by CRISPR/Cas9 validated Selective Inhibitor of Nuclear Export (SINE) compounds (selinexor and analogs) restores the antitumor activity of multiple TSPs leading to suppression of PDAC in vitro and in orthotopic models. Experimental Design: We evaluate the synergy between SINE compounds and standard-of-care treatments in preclinical models and in a PDAC Phase Ib trial. Results: SINE compounds synergize with gemcitabine (GEM) and nanoparticle albumin–bound (nab)-paclitaxel leading to suppression of PDAC cellular growth and cancer stem cell (CSC) spheroids disintegration. Label-free quantitative proteome profiling with nuclear and cytoplasmic enrichment showed superior enhancement in nuclear protein fraction in combination treatment. Selinexor inhibited the growth of PDAC CSC and two patient-derived (PDX) subcutaneous xenografts. Selinexor–GEM–nab-paclitaxel blocked PDX and orthotopic tumor growth. In a phase 1b study (NCT02178436), 9 patients were exposed to selinexor (60 mg oral) with GEM (1,000 mg/m2 i.v.) and nab-paclitaxel (125 mg/m2 i.v.) on days 1, 8, and 15 of 28-day cycle. Two patients showed partial response, and 2 had stable disease. An outstanding, durable objective response was observed in one of the responders with progression-free survival of 16 months and overall survival of 22 months. Conclusions: Our preclinical and ongoing clinical study lends support to the use of selinexor–GEM–nab-paclitaxel as an effective therapy for metastatic PDAC.